Determining the significance of MGUS

Systemic light chain amyloidosis: an update for treating physicians

(2013) G. Merlini et al.   BLOOD

Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden

(2013) I. Turesson et al.   BLOOD

Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center.

(2013) A Dispenzieri et al.   BONE MARROW TRANSPLANTATION

Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma

(2013) María-Victoria Mateos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant

(2012) N. Leung et al.   BLOOD

Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS

(2012) J A Katzmann et al.   LEUKEMIA

Incidence of Monoclonal Gammopathy of Undetermined Significance and Estimation of Duration Before First Clinical Recognition

(2012) Terry M. Therneau et al.   MAYO CLINIC PROCEEDINGS

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

(2010) R A Kyle et al.   LEUKEMIA